Who Exports Bevacizumab from India — 196 Suppliers Behind a $46.9M Market
India's bevacizumab export market is supplied by 196 active exporters who collectively shipped $46.9M across 1,408 shipments. DR.REDDY'S LABORATORIES LTD leads with a 47.2% market share, followed by BIOCON BIOLOGICS INDIA LIMITED and DR REDDY S LABORATORIES LTD. The top 5 suppliers together control 83.9% of total export value, reflecting a concentrated market structure.
Top Bevacizumab Exporters from India — Ranked by Export Value
DR.REDDY'S LABORATORIES LTD is the leading bevacizumab exporter from India, holding a 47.2% share of the $46.9M market across 1,408 shipments from 196 exporters. The top 5 suppliers — DR.REDDY'S LABORATORIES LTD, BIOCON BIOLOGICS INDIA LIMITED, DR REDDY S LABORATORIES LTD, RELIANCE LIFE SCIENCES PRIVATE LIMITED, ZYDUS LIFESCIENCES LIMITED — collectively control 83.9% of total export value, indicating a highly concentrated market. Individual shares are: DR.REDDY'S LABORATORIES LTD (47.2%), BIOCON BIOLOGICS INDIA LIMITED (18.4%), DR REDDY S LABORATORIES LTD (9.9%), RELIANCE LIFE SCIENCES PRIVATE LIMITED (4.5%), ZYDUS LIFESCIENCES LIMITED (3.8%).
Top Bevacizumab Exporters from India
Ranked by export value · 196 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | DR.REDDY'S LABORATORIES LTD BEVACIZUMAB SUBSTANCE-FROZEN SOLUTION COBEVACIZUMAB WCBPERSIVIA 100MG/4ML)(QTY: | $22.1M | 15 | 47.2% |
| 2 | BIOCON BIOLOGICS INDIA LIMITED ABEVMY 25 MG/ML BEVACIZUMABABEVMY 25 MG/ML (BEVACIZUMABABEVMY 25 MG/ML (BEVACIZUMAB INJECTION | $8.6M | 12 | 18.4% |
| 3 | DR REDDY S LABORATORIES LTD BEVACIZUMAB SUBSTANCE-FROZEN SOLUTION COBEVACIZUMAB WCBPERSIVIA 100MG/4ML)(QTY: | $4.6M | 1 | 9.9% |
| 4 | RELIANCE LIFE SCIENCES PRIVATE LIMITED BEVACIZUMAB INJECTIONBEVACIZUMAB INJECTION 400 MG/16MLMEDICINE FOR HUMAN CONSUMPTION : BEVACIZUMAB 400 MG / 16 ML | $2.1M | 12 | 4.5% |
| 5 | ZYDUS LIFESCIENCES LIMITED BHAVAVIALSLMXBEVACIZUMAB SOLUTION FOR INFUSION 400MGBEVACIZUMAB 400MG INJ | $1.8M | 4 | 3.8% |
| 6 | DR REDDYS LABORATORIES LIMITED BEVACIZUMAB SUBSTANCE-FROZEN SOLUTION COBEVACIZUMAB WCBPERSIVIA 100MG/4ML)(QTY: | $1.2M | 4 | 2.5% |
| 7 | MYLAN PHARMACEUTICALS PRIVATE LIMITED BEVACIZUMAB SOLUTION FOR INFUSION 400MGBEVACIZUMAB 400MG INJBEVACIZUMAB CSI 400MG/16ML 1 VL IN MY | $809.4K | 5 | 1.7% |
| 8 | DR.REDDY'S LABORATORIES LIMITED BEVACIZUMAB SUBSTANCE-FROZEN SOLUTION COBEVACIZUMAB WCBPERSIVIA 100MG/4ML)(QTY: | $653.3K | 4 | 1.4% |
| 9 | HETERO BIOPHARMA LIMITED | $282.5K | 3 | 0.6% |
| 10 | DR REDDY S LABORATORIES LIMITED BEVACIZUMAB SUBSTANCE-FROZEN SOLUTION COBEVACIZUMAB WCBPERSIVIA 100MG/4ML)(QTY: | $275.0K | 3 | 0.6% |
| 11 | ANDEL HEALTHCARE | $236.1K | 1 | 0.5% |
| 12 | R.S. SURGIPHARM PRIVATE LIMITED BEVACIZUMAB SOLUTION FOR INFUSION 400MGBEVACIZUMAB 400MG INJBEVACIZUMAB CSI 400MG/16ML 1 VL IN MY | $214.1K | 2 | 0.5% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Bevacizumab exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Dr. Reddy's Laboratories Ltd. | Approved | Yes | Yes | Multiple | Dr. Reddy's has received FDA approvals for various products and holds WHO-GMP an |
| Biocon Limited | Approved | Yes | Yes | Multiple | Biocon has received FDA approvals and holds WHO-GMP and EU GMP certifications. |
| Zydus Lifesciences Limited | Approved | Yes | Yes | Multiple | Zydus Lifesciences has received FDA approvals and holds WHO-GMP and EU GMP certi |
| Reliance Life Sciences Private Limited | Approved | Yes | Yes | Multiple | Reliance Life Sciences has received FDA approvals and holds WHO-GMP and EU GMP c |
| Mylan Pharmaceuticals Private Limited | Approved | Yes | Yes | Multiple | Mylan Pharmaceuticals has received FDA approvals and holds WHO-GMP and EU GMP ce |
| Hetero Biopharma Limited | Approved | Yes | Yes | Multiple | Hetero Biopharma has received FDA approvals and holds WHO-GMP and EU GMP certifi |
| Dr. Reddy's Biologics | Approved | Yes | Yes | Multiple | Dr. Reddy's Biologics has received FDA approvals and holds WHO-GMP and EU GMP ce |
| Biocon Biologics India Limited | Approved | Yes | Yes | Multiple | Biocon Biologics has received FDA approvals and holds WHO-GMP and EU GMP certifi |
| Zydus Biologics | Approved | Yes | Yes | Multiple | Zydus Biologics has received FDA approvals and holds WHO-GMP and EU GMP certific |
TransData Nexus reviewed the regulatory standing of 9 leading Bevacizumab exporters from India. 9 hold US FDA facility approvals, 9 maintain WHO-GMP certification, and 9 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Bevacizumab sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often dubbed the "Bulk Drug Capital of India," is a pivotal hub for active pharmaceutical ingredients (APIs) and bulk drug manufacturing. The city hosts numerous pharmaceutical companies, including Hetero Biopharma Limited, which launched a biosimilar of Bevacizumab named Cizumab in June 2016. This underscores Hyderabad's significant role in the biosimilar segment, contributing substantially to both domestic supply and exports.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. This region is home to major players like Zydus Lifesciences Limited, which has been instrumental in the production and export of Bevacizumab formulations. The cluster's emphasis on formulations complements the bulk drug production in other regions, ensuring a comprehensive supply chain for biosimilars.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for Indian pharmaceuticals. Companies such as Reliance Life Sciences Private Limited, based in this region, have developed biosimilars like Bevacizumab, facilitating their distribution to international markets. The strategic location and well-established infrastructure make this cluster vital for the export of biosimilars.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, primarily due to favorable tax incentives. While specific data on Bevacizumab production in this cluster is limited, the region's overall contribution to the pharmaceutical sector is noteworthy.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.
- Evaluate Supplier Capabilities: Assess the technical expertise and regulatory compliance of suppliers, especially for complex biosimilars like Bevacizumab.
- Monitor Export Trends: Stay informed about export data and market demands to align sourcing strategies with global needs.
- Leverage Regional Strengths: Utilize the specific strengths of each pharmaceutical cluster to optimize the supply chain for Bevacizumab.
By understanding the unique contributions of India's pharmaceutical clusters, stakeholders can make informed decisions to enhance the efficiency and reliability of sourcing Bevacizumab.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Bevacizumab exporters from India
Zydus Lifesciences Limited — Zydus receives Mexican approval for Bevacizumab biosimilar
In July 2024, Zydus Lifesciences received marketing approval from the Mexican regulatory authority for Bhava™, its biosimilar of Bevacizumab. - IMPACT: This approval is expected to enhance Zydus's Bevacizumab exports to Mexico, contributing to the company's growth in the Latin American market.
Impact: This approval is expected to enhance Zydus's Bevacizumab exports to Mexico, contributing to the company's growth in the Latin American market.
Zydus Lifesciences Limited — Zydus acquires Agenus's CDMO business
In June 2025, Zydus Lifesciences acquired the contract development and manufacturing organization (CDMO) business of Agenus, including two biologics manufacturing sites in Emeryville and Berkeley. - IMPACT: This acquisition is anticipated to bolster Zydus's biologics manufacturing capabilities, potentially increasing Bevacizumab production capacity.
Impact: This acquisition is anticipated to bolster Zydus's biologics manufacturing capabilities, potentially increasing Bevacizumab production capacity.
Zydus Lifesciences Limited — Zydus receives USFDA approval for prostate cancer drug
In October 2024, Zydus Lifesciences received approval from the USFDA to manufacture enzalutamide tablets, used for treating prostate cancer. - IMPACT: While not directly related to Bevacizumab, this approval signifies Zydus's expanding oncology portfolio, which may positively influence its overall export strategy.
Impact: While not directly related to Bevacizumab, this approval signifies Zydus's expanding oncology portfolio, which may positively influence its overall export strategy.
Zydus Lifesciences Limited — Zydus receives Mexican approval for Bevacizumab biosimilar
In July 2024, Zydus Lifesciences received marketing approval from the Mexican regulatory authority for Bhava™, its biosimilar of Bevacizumab. - IMPACT: This approval is expected to enhance Zydus's Bevacizumab exports to Mexico, contributing to the company's growth in the Latin American market.
Impact: This approval is expected to enhance Zydus's Bevacizumab exports to Mexico, contributing to the company's growth in the Latin American market.
Zydus Lifesciences Limited — Zydus acquires Agenus's CDMO business
In June 2025, Zydus Lifesciences acquired the contract development and manufacturing organization (CDMO) business of Agenus, including two biologics manufacturing sites in Emeryville and Berkeley. - IMPACT: This acquisition is anticipated to bolster Zydus's biologics manufacturing capabilities, potentially increasing Bevacizumab production capacity.
Impact: This acquisition is anticipated to bolster Zydus's biologics manufacturing capabilities, potentially increasing Bevacizumab production capacity.
Zydus Lifesciences Limited — Zydus receives USFDA approval for prostate cancer drug
In October 2024, Zydus Lifesciences received approval from the USFDA to manufacture enzalutamide tablets, used for treating prostate cancer. - IMPACT: While not directly related to Bevacizumab, this approval signifies Zydus's expanding oncology portfolio, which may positively influence its overall export strategy.
Impact: While not directly related to Bevacizumab, this approval signifies Zydus's expanding oncology portfolio, which may positively influence its overall export strategy.
Common Questions — Bevacizumab Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which bevacizumab supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, DR.REDDY'S LABORATORIES LTD leads with 131 recorded shipments worth $22.1M. BIOCON BIOLOGICS INDIA LIMITED (46 shipments) and DR REDDY S LABORATORIES LTD (14 shipments) are also established high-volume exporters.
Q How many bevacizumab manufacturers are there in India?
India has 196 active bevacizumab exporters with a combined export market of $46.9M across 1,408 shipments to 100 countries. The top 5 suppliers hold 83.9% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for bevacizumab from India?
Average FOB unit price: $147.11 per unit, ranging from $0.00 to $3098.55. Average shipment value: $33.3K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 196 verified Indian exporters of Bevacizumab ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 1,408 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 100 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1,408 Verified Shipments
196 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists